Holo-Lactoferrin Modified Liposome for Relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Holo-Lactoferrin Modified Liposome for Relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer
Authors
Keywords
-
Journal
Small
Volume -, Issue -, Pages 1803703
Publisher
Wiley
Online
2019-01-16
DOI
10.1002/smll.201803703
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanoscale Metal–Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy
- (2018) Guangxu Lan et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Noninvasive89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer
- (2017) Kelly E. Henry et al. JOURNAL OF NUCLEAR MEDICINE
- Continuous O2-Evolving MnFe2O4 Nanoparticle-Anchored Mesoporous Silica Nanoparticles for Efficient Photodynamic Therapy in Hypoxic Cancer
- (2017) Jonghoon Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses
- (2017) Guangbao Yang et al. Nature Communications
- Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19 F–MRI and Multispectral Analysis
- (2017) Yunzhou Shi et al. NEOPLASIA
- Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy
- (2016) Liangzhu Feng et al. ACS Nano
- Cisplatin-Prodrug-Constructed Liposomes as a Versatile Theranostic Nanoplatform for Bimodal Imaging Guided Combination Cancer Therapy
- (2016) Liangzhu Feng et al. ADVANCED FUNCTIONAL MATERIALS
- Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
- (2016) René Baumann et al. Expert Review of Anticancer Therapy
- One-Step Self-Assembling Method to Prepare Dual-Functional Transferrin Nanoparticles for Antitumor Drug Delivery
- (2016) Kaikai Wang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
- (2016) Anita K. Bakrania et al. PHARMACOLOGICAL RESEARCH
- Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice
- (2016) Jayanth Suryanarayanan Shankaranarayanan et al. Scientific Reports
- LNA aptamer based multi-modal, Fe 3 O 4 -saturated lactoferrin (Fe 3 O 4 -bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging
- (2015) Kislay Roy et al. BIOMATERIALS
- Radionuclide 131I labeled reduced graphene oxide for nuclear imaging guided combined radio- and photothermal therapy of cancer
- (2015) Lei Chen et al. BIOMATERIALS
- Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer
- (2015) Jessica A. Gibbons et al. BMC CANCER
- Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
- (2015) Feifei Teng et al. CANCER LETTERS
- Opportunities and challenges of radiotherapy for treating cancer
- (2015) Dörthe Schaue et al. Nature Reviews Clinical Oncology
- Science to Practice: Can Photoacoustic Imaging Be Used to Monitor Tumor Oxygenation and the Effects of Antivascular Chemotherapies?
- (2015) Mark D. Pagel RADIOLOGY
- Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice
- (2014) Kanyi Pu et al. Nature Nanotechnology
- Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy
- (2014) Yunlei Zhang et al. NUTRITION REVIEWS
- In vivophotoacoustic lifetime imaging of tumor hypoxia in small animals
- (2013) Qi Shao et al. JOURNAL OF BIOMEDICAL OPTICS
- The proton permeability of self-assembled polymersomes and their neuroprotection by enhancing a neuroprotective peptide across the blood–brain barrier after modification with lactoferrin
- (2013) Yuan Yu et al. Nanoscale
- “Iron-saturated” bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice
- (2012) Xueying Sun et al. BMC CANCER
- Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
- (2012) Jagat Kanwar et al. International Journal of Nanomedicine
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- (2011) Tracy R. Daniels et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells
- (2011) Megumi Kawamoto et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin
- (2011) Tove J. Evjen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance
- (2011) Kristi Hendrickson et al. RADIOTHERAPY AND ONCOLOGY
- Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery
- (2010) Huali Chen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- ‘Iron-saturated’ lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy
- (2008) Jagat R Kanwar et al. IMMUNOLOGY AND CELL BIOLOGY
- Direct regulation of TWIST by HIF-1α promotes metastasis
- (2008) Muh-Hwa Yang et al. NATURE CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More